Acute lymphoblastic leukemia
Conditions
Interventions
Standard risk group:Inductive therapy (Pred+VDLP)+Early intensive therapy (CAM1)+Consolidation therapy (M)+Delay intensive therapy (VDLD+CAM)+Maintenance thrapy (6-MP+MTX/VD)
Intermediate risk group:Inductive therapy (Pred+VDLP)+Early intensive therapy (CAML×2)+Consolidation therapy (M)+Delay intensive therapy (VDLD+CAML×2)+Maintenance thrapy (6-MP+MTX/VD)
High risk group:Inductive therapy (Pred+VDLD)+Early intensive therapy (CAML×2)+Consolidation therapy (HR-1, HR-2, HR-3)×2+Delay intensive therapy (VDLD+CAML)+Maintenance thrapy (6-MP+MTX/VD)
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1, less than 18 years old; 2. The diagnosis was acute lymphoblastic leukemia (ALL). The immunophenotype was B precursor lymphocyte phenotype. 3. New patients.
Exclusion criteria
Exclusion criteria: 1. Mature B or Acute ambiguous lineage leukemia; 2. Secondary to immunodeficiency disease; 3. Second tumor; 4. CML zag leukemia; 5. ALL with Down 'S syndrome; 6. The glucocorticoid is used for more than one week or other radiochemotherapy one month before in the group
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bone marrow minimal residual disease; | — |
Countries
China
Contacts
Public ContactWang Tianyou
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed